

Brief Summary

See package insert for full prescribing information.

Indications and Usago: Effector XR is indicated for the treatment of depression and for the treatment of Generalized
Annety Disorder (All-Born XR is contradicated in a batteris known to be hypersonalitive to vendafazine hydrochloride.

Contradications: (All-Born XR is contradicated in a batteris known to be hypersonalitive to vendafazine hydrochloride.

Contradications: (All-Born XR is contradicated in patients (MADIs) is contradicated (see "Warnings", or with the contradication of the contradicati

machinery, including automobiles, until they are reasonably sure that venidavine does not adversely affect their abilities. Fell patients to 1) notify their physician if they become pregnant or intend to become pregnant during the rapy, or if they are nursing; 2) inform physician about other prescription or over the counter medications they are taking or plan to take; 3) avoid alchoric while taking Effexox XR, 4) notify their physician if they develop a rash, hives, or related allergic phenomena.

ABORATON FENDEN—Climetidine: Use with caution when administering venidazine with circuit medications that the patient shall be presented to the patient of the patient shall be presented to the patients with pre-existing hypertension or hepatic dystunction, and the elderly.

\*\*Haloperidol\*\* Venidazine\*\* 150 mg/day/ decreased total oral-does clearance (CVF) of haloperidol which resulted in a CVS increase in haloperidol AUC. The haloperidol climal increase of Bave when coadministered with venidazine, but the haloperidol elimination half-life was unchanged.


\*\*Drugs inhibiting Cytochrome P4502D6.\*\* Drugs inhibiting this isoenzyme have the potential to increase plasma concentrations of Venidazine and ODV are essentially unchanged in CVF206 poor metabolizers, no dosage adjustment is required when a cytochrome P4502D6.\*\* Drugs inhibiting the potentially inhibits both CVF206 and CVF2A4, the primary metabolizing enzymes for venidazione and one of venidazione and one of venidazione and one of venidazione and one of venidazione development of venidazio

of pacobo in depression basis ecluded: nausou, aroceal, dry medit. dezirees, incomais, and someciner, in U.S. places occretoride depression tasis recluded hypotheristics, denther, passedhesis, thems, aborted intolly blumd procession. A procession of the processio

WYETH-AYERST LABORATORIES

© 2000. Wyeth-Averst Laboratories

79345-00



the ability to achieve recovery.1

Visit us at www.EFFEXORXR.com

Please see brief summary of Prescribing Information on adjacent page.

## The efficacy and safety of EFFEXOR XR for pediatric use have not been established.

EFFEXOR XR is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). EFFEXOR XR should not be used in combination with an MAOI or within at least 14 days of discontinuing treatment with an MAOI; at least 7 days should be allowed after stopping EFFEXOR XR before starting an MAOI.

The most common adverse events reported in EFFEXOR XR placebo-controlled depression trials (incidence ≥10% and ≥2× that of placebo) were nausea, dizziness, somnolence,

abnormal ejaculation, sweating, dry mouth, and nervousness; and in GAD trials were nausea, dry mouth, insomnia, abnormal ejaculation, anorexia, constipation, nervousness, and sweating.

Treatment with venlafaxine is associated with sustained increases in blood pressure (BP) in some patients. Three percent of EFFEXOR XR patients in depression studies (doses of 75 to 375 mg/day) and 0.4% in GAD studies (doses of 75 to 225 mg/day) had sustained BP elevations. Less than 1% discontinued treatment because of elevated BP. Regular BP monitoring is recommended.

Reference: 1. Data on file, Wyeth-Ayerst Laboratories, Philadelphia, Pa.

Published online by Cambridge University Press